Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy AlloVir stock | $24.67

Learn how to easily invest in AlloVir stock.

AlloVir Inc is a biotechnology business based in the US. AlloVir shares (ALVR) are listed on the NASDAQ and all prices are listed in US Dollars. AlloVir employs 100 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in AlloVir

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALVR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AlloVir stock price (NASDAQ: ALVR)

Use our graph to track the performance of ALVR stocks over time.

AlloVir shares at a glance

Information last updated 2021-10-23.
Latest market close$24.67
52-week range$16.66 - $48.96
50-day moving average $23.01
200-day moving average $21.45
Wall St. target price$46.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.06

Buy AlloVir shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AlloVir stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AlloVir price performance over time

Historical closes compared with the close of $24.67 from 2021-10-25

1 week (2021-10-19) 5.02%
1 month (2021-09-24) 6.80%
3 months (2021-07-26) 33.50%
6 months (2021-04-26) 4.89%
1 year (2020-10-26) -4.97%
2 years (2019-10-22) N/A
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

AlloVir financials

Gross profit TTM $165,000
Return on assets TTM -33.07%
Return on equity TTM -58.04%
Profit margin 0%
Book value $4.91
Market capitalisation $1.6 billion

TTM: trailing 12 months

Shorting AlloVir shares

There are currently 2.8 million AlloVir shares held short by investors – that's known as AlloVir's "short interest". This figure is 1.5% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting AlloVir shares can be evaluated.

AlloVir's "short interest ratio" (SIR)

AlloVir's "short interest ratio" (SIR) is the quantity of AlloVir shares currently shorted divided by the average quantity of AlloVir shares traded daily (recently around 273940.25218235). AlloVir's SIR currently stands at 10.31. In other words for every 100,000 AlloVir shares traded daily on the market, roughly 10310 shares are currently held short.

However AlloVir's short interest can also be evaluated against the total number of AlloVir shares, or, against the total number of tradable AlloVir shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AlloVir's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AlloVir shares in existence, roughly 40 shares are currently held short) or 0.128% of the tradable shares (for every 100,000 tradable AlloVir shares, roughly 128 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AlloVir.

Find out more about how you can short AlloVir stock.

AlloVir share dividends

We're not expecting AlloVir to pay a dividend over the next 12 months.

AlloVir overview

Allovir, Inc. , a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.

Frequently asked questions

What percentage of AlloVir is owned by insiders or institutions?
Currently 51.296% of AlloVir shares are held by insiders and 41.047% by institutions.
How many people work for AlloVir?
Latest data suggests 100 work at AlloVir.
When does the fiscal year end for AlloVir?
AlloVir's fiscal year ends in December.
Where is AlloVir based?
AlloVir's address is: 139 Main Street, Cambridge, MA, United States, 02142
What is AlloVir's ISIN number?
AlloVir's international securities identification number is: US0198181036

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site